Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 1 3Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Healthy, no Evidence of Disease 1Breast Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × 3,3'-diindolylmethane × Clear all
NCT00784394 2016-12-29

Diindolylmethane in Preventing Cancer in Healthy Volunteers

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled

Healthy, no Evidence of Disease

NCT00450229 2015-12-04

Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer

National Cancer Institute (NCI)

Phase 1 Completed
45 enrolled
Genitourinary

Prostatic Neoplasms

NCT01022333 2009-12-01

The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers

Women's College Hospital

Phase 1 Unknown
300 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡